ArticleAntimicrobial agents and chemotherapy2020
Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities.
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Antibacterial potential of five phages in controlling Enterococcus faecalis and Enterococcus faecium.Virology journal · 2026Article
- Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.Viruses · 2026Review
- The virulent bacteriophage Henu8 as an antimicrobial synergist againstMicrobiology spectrum · 2025Article
- Bacteriophage Therapy as a Promising Alternative for Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics.Nature reviews. Microbiology · 2024Review
- Antibacterial and Antibiofilm Potential of Bacterial Cellulose Hydrogel Containing Vancomycin against Multidrug-ResistantBiology · 2024Article
- A simple solid media assay for detection of synergy between bacteriophages and antibiotics.Microbiology spectrum · 2024Article
- The virtue of training: extending phage host spectra against vancomycin-resistantAntimicrobial agents and chemotherapy · 2024Article
- Article
- Exploiting phage-antibiotic synergies to disruptMicrobiology spectrum · 2024Article
- Phage-antibiotic combinations against multidrug-resistantAntimicrobial agents and chemotherapy · 2023Article
- Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial VegetationMicrobiology spectrum · 2023Article
- Bactericidal Synergism between Phage YC#06 and Antibiotics: a Combination Strategy to Target Multidrug-Resistant Acinetobacter baumanniiMicrobiology spectrum · 2022Article
- Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Benefits of Combined Phage-Antibiotic Therapy for the Control of Antibiotic-Resistant Bacteria: A Literature Review.Antibiotics (Basel, Switzerland) · 2022Review
- Synergistic Effects of Bacteriophage vB_Eco4-M7 and Selected Antibiotics on the Biofilm Formed by Shiga Toxin-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus InfectionsMicrobiology spectrum · 2022Article
- Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.Journal of biomedical science · 2022Review
- Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-Embedded MDRAntibiotics (Basel, Switzerland) · 2022Article
- Considerations for the Use of Phage Therapy in Clinical Practice.Antimicrobial agents and chemotherapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Taylor MorrisetteAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID 0000-0002-1094-043X
Katherine L LevAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Razieh KebriaeiAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Jacinda C Abdul-MutakabbirAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Kyle C StamperAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Sandra MoralesPhage Consulting, Sydney, New South Wales, Australia.
Susan M LehmanCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Gregory S CanfieldDepartment of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA.
Breck A DuerkopDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.ORCID 0000-0003-4030-9822
Cesar A AriasDivision of Infectious Diseases and Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), UTHealth, McGovern Medical School, Houston, Texas, USA.
Michael J RybakAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA m.rybak@wayne.edu.ORCID 0000-0003-2220-0081
Eugene Applebaum College of Pharmacy and Health Sciences · USUniversity of Colorado Denver · USCenter for Biologics Evaluation and Research · USUniversidad El Bosque · CO
Funding
Mechanistic basis of bacteriophages for the decolonization of vancomycin resistant enterococci in the intestine.R01AI141479 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DUERKOP, BRECK A · 2018 to 2025
$4.4MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MA Pharmacologic Approach to Prevent Daptomycin Resistance in VRER01AI121400 · NIAID · WAYNE STATE UNIVERSITY · PI RYBAK, MICHAEL JOSEPH · 2016 to 2020
$1.9MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MMolecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442kNIAID NIH HHS K24 AI121296NIAID NIH HHS R01 AI121400NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI141479NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI143229
Abstract
Concerns regarding increased prevalence of daptomycin (DAP)-resistant strains necessitate novel therapies for
Indexed as
Anti-Bacterial AgentsDaptomycinEnterococcus faeciumPhage TherapyBacteriophagesGram-Positive Bacterial InfectionsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsDaptomycinbacteriophage-antibiotic combinationsbacteriophagesdaptomycinEnterococcus faecium
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.